Cutaneous toxicity as a predictive biomarker for clinical outcome in patients receiving anticancer therapy

Keyphrases

• Clinical Outcomes 100%
• Prognostic Biomarker 100%
• Anticancer Therapy 100%
• Cutaneous Toxicity 100%
• Treatment Efficacy 25%
• Survival Benefit 25%
• Molecular Targets 25%
• Anticancer 25%
• Patient Outcomes 25%
• Patients with Cancer 25%
• Treatment Outcome 25%
• Treatment Decisions 25%
• Decision Outcomes 25%
• Oncologists 25%
• Main Class 25%
• Treatment Paradigms 25%
• Multikinase Inhibitor 25%
• Multidisciplinary Treatment 25%
• Dermatologist 25%
• Increased Awareness 25%
• Surrogate Biomarker 25%
• Immune Checkpoint Inhibitors 25%

Nursing and Health Professions

• Clinical Outcome 100%
• Biological Marker 100%
• Skin Toxicity 100%
• Anticancer 100%
• Treatment Outcome 50%
• Efficacy 50%
• Oncologist 25%
• Dermatological Agent 25%
• Dermatologist 25%
• Phosphotransferase Inhibitor 25%

Pharmacology, Toxicology and Pharmaceutical Science

• Biological Marker 100%
• Skin Toxicity 100%
• Malignant Neoplasm 25%
• Phosphotransferase Inhibitor 25%
• Prospective Study 25%
• Dermatological Agent 25%
• Immune Checkpoint Inhibitor 25%